Source: http://radiotec.ru/article/12856
Timestamp: 2019-04-25 16:34:11+00:00

Document:
At oncological patients the iron metabolism is broken, and at 40 – 70 % of oncological patients the anemia of chronic disease develops. Modern diagnostics the anemia of chronic disease is based on concentration definition ferritin, a soluble receptor transferrin and hepcidin. Last years, in experiment, it is shown that as a result of action IL-6 production in a liver the squirrel hepcidin, which blocks iron absorption in a duodenal gut and recycling gland macrophages raises. Functional deficiency of iron develops. Last years interest to ferritin as to «the tumor-associated to the squirrel» has increased. Many works are devoted research ferritin at malignant diseases. A number of authors is considered by indicators of concentrationferritin, as prognostic criterion of survival rate of oncological patients. Now there is an accumulation of data on biological and clinical importance ferritin. Ferritin and especially its H-isoform should take the place among clinically significant tumoral markers from a class of «the tumor-associated products of synthesis» which can be used for monitoring at treatment of oncological diseases.
Nemeth E., Tuttle M.S., Powelson J. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization // Science. 2004. V. 306. P. 2090 – 2093.
Hguyen N.B., Callaghan K.D., Ghio A.J. et al. Hepcidin expression and iron transport in alveolar macrophages // Am. J. Physiol. Lung Cell Mol. Physiol. 2006. V. 291. № 3. P. 417 – 425.
Testa U. Recent developments in the understanding of iron metabolism // J. Hematol. 2002. V. 3. №2. P. 63 – 89.
PavlovA.D., MorshhakovaE.F., RumjancevA.G.EHritropoehz, ehritropoehtin, zhelezo. Molekuljarnye i klinicheskie aspekty / M.:«GEHOTAR-Media». 2011. 320 s.
Andreev G.I. Ferritin kak marker zhelezodeficitnojj anemii i opukholevyjj marker // Internet-zhurnal «Kommercheskaja biotekhnologija». 2004. № 4. S. 1 – 15.
Harrison P.M., Treffry A., Lilley T.H.Ferritin as an iron-storage protein: mechanisms of iron uptake // J. Inorg. Biochemistry. 1986. V. 27. P. 287 – 293.
Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation // Biochim. Biophys. Acta. 1996. V. 1275. P. 161 – 203.
Lubjanova I.P. Sovremennye predstavlenija o metabolizme zheleza s pozicii profpatologa // Aktualnye problemy transportnojj mediciny. 2010. № 2. S. 47 –57.
Lu J.P., Hayashi K., Awai M.Transferrin receptor expression in normal, iron-deficient and iron-overloaded rats // Acta Pathol. Jpn. 1989. № 39. P. 759 – 764.
Lapin A. Rastvorimyjj receptor transferrina («soluble transferrin receptor»): novyjj parametr dlja opredelenija statusa zheleza // Rossijjskaja Associacija medicinskojj laboratornojj diagnostiki // Laboratornaja medicina. 2002. № 5. S. 1 – 6.
Bokova E.V., Karamjan N.A., Kazanec E.G. Diagnosticheskie vozmozhnosti opredelenija rastvorimykh transferrinovykh receptorov (obzor literatury) // Voprosy gematol. onkol. immun. v pediatrii. 2004. T. 3. № 2. S. 15 - 17.
Leibold E.A., Munro H.N.Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5\' untranslated region of ferritin heavy- and light-subunit mRNAs // Proc. Natl. Acad. Sci. USA. 1988. V.85. № 4. P. 2171 – 2175.
Dickey L.F., Sreedharan S., Theil E.C. et al.Multiple red cell ferritin mRNAs, which code for an abundant protein in the embryonic cell type, analyzed by cDNA sequence and by primer extension of the 5\'-untranslated regions // J. Biol. Chem. 2001. V. 261. № 3. P. 949 – 955.
Blindar V.N., Zubrikhina G.N., Matveeva I.I. Rastvorimyjj receptor transferrina: novyjj laboratornyjj test obektivnojj ocenki metabolizma zheleza onkologicheskikh bolnykh // Vestnik RONC im. N.N.BlokhinaRAMN. 2009. T. 20. № 4. S. 4 – 7.
Jacobs A., Miller F., Worwood M. et al. Ferritin in serum of normal subjects and patients with iron deficiency and iron overload // Br. Med. J. 1972. V. 4. P. 206 – 208.
Blindar V.N., Zubrikhina G.N, Matveeva I.I. Algoritm sovremennojj laboratornojj diagnostiki anemicheskogo sindroma onkologicheskikh bolnykh // Klin. Lab. Diagn. 2012. № 7. S. 19 – 24.
Reissman K.R., Dietrich M.R. On the presence of ferritin in the peripheral blood of patients with hepatocellular disease // J. Clin. Invest. 1956. V. 35.P. 588–595.
Miles L.E., Lipschitz D.A., Bieber C.P., Cook J.D. Measurement of serum ferritin by a 2-site immunoradiometric assay // Analyt. Biochem. 1974. V. 61. P. 209 – 224.
Munro H.N., Linder M.C. Ferritin structure, biosynthesis, and function // Physiologic. Rev. 1978. V.58. P. 317 – 396.
Levi S., Yewdall S.J., Rovida E., Arosio P. Evidence of H- and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin // Biochem. J. 1992. V. 288. P. 591 – 596.
Santoro C., Marone M., Silengo L. Cloning of the gene coding for human L apoferritin // Nucleic Acids Res. 1986. V. 14. P. 2863 – 2876.
Lawson D.M., Artymiuk P.J., Yewdall S.J. et al. Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts // Nature. 1991. V. 349. P. 541 – 544.
Sun S., Arosio P., Levi S., Chasteen N.D.Ferroxidase kinetics of human liver apoferritin, recombinant H-chain apoferritin, and site-directed mutants // Biochemistry. 1993. V. 32. P. 9362 – 9369.
Andrews S.C., Treffery A., Harrison P.M. Siderosomal ferritin. The missing link between ferritin and haemosiderin // Biochem J. 1987. V. 245. P. 439 – 446.
Thomas C., Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis // Lab. Hemat. 2005. V. 11. № 1. P. 14 – 23.
Smirnova L.A. Marcev S.P. Ferritin i ego klinicheskoe znachenie // Medicinskie novosti. 1996. № 7. S. 11 –15.
Grail A., Hancock B.W., Harrison P. Serum ferritin in normal individuals and in patients with malignant lymphoma and chronic renal failure measured with seven different commercial immunoassay techniques // J. Clin. Pathol. 1982. V. 35. № 6. P. 1204 – 1212.
Vitorgan JU.E. Klinicheskoe primenenie immunologicheskikh testov pri rannikh formakh raka molochnojj zhelezy // Sb.: «Immunologicheskie aspekty diagnostiki zlokachestvennykh novoobrazovanijj». M. 1988. 93 s.
Mahindra F., Bolwell B., Sobecks R. et al. Elevated ferritin is associated with relapse after autologous hemopoietic stem cell transplantation for lymphoma // Biol. Blood Marrow Transpl. 2008. V. 14. P. 1239 – 1244.
Kataoka K., Nannya Y., Hangaishi A. et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation // Biol. Blood Marrow Transpl. 2009. V. 15. P. 195 –204.
Grjaznova I.M., Borisenko S.A., Makarov O.V. i dr. Syvorotochnyjj ferritin i TBG pri opukholjakh polovykh organov u zhenshhin // Voprosy onkologii. 1990. № 2. S. 181 –187.
Hann H.L., Stahlhut M.W., Blumberg B.S. Iron nutrition and tumor growth: decreased tumor growth in iron deficient mice // Cancer Res. 1988. V. 48. P. 4168 –4170.
Hann H.L., Stahlhut M.W., Evans A.E. Basic and acidic isoferritins in the sera of patients with neuroblastoma // Cancer. 1988. V. 62. P. 1179 –1182.
Zhou X.D., Stahlhut M.W., Hann H.L., London W.T. Serum ferritin in hepatocellular carcinoma // Hepatogastroenterology. 1988. V. 35. P. 1 –4.
Hann H.L. Prevention of Primary Hepatocellular Carcinoma // Bulletin, Korean Medical Association of America. 1988. V. 13. № 2. P. 9 –10.
Hann H.L., Kim C.Y., London W.T., Blumberg B.S. Increased serum ferritin in chronic liver disease: A risk factor for primary hepatocellular carcinoma // Int. J. Cancer. 1989. V. 43. P. 376 – 379.
Drysdale J.W. Ferritin as a tumour marker // J. Clin. Immunoassay. 1983. V. 15. № 6.P. 234 –240.
Hann H.L., Lange B.J., Stahlhut M.W., McGlynn K.A. Prognostic importance of serum transferrrin and ferritin in childhood Hodgkin\'s disease // Cancer. 1990. V. 66. P. 313 –316.
Saraeva N.O. Mekhanizmy razvitija anemii pri gemoblastozakh // Gematol. Transfuziol. 2007. T.52. № 1. S. 31 – 37.
Saraeva N.O., Belokhvostikova T.S., Potrachkova T.G. i dr. Citokiny: rol v razvitiii anemii u bolnykh mnozhestvennojj mielomojj i khronicheskim mielolejjkozom // Citokiny i vospalenie. 2005. T. 4. № 3. S. 16 – 19.
Saraeva N.O., Gorokhova L.A., KHoroshikh O.V. i dr. Mekhanizmy razvitija anemii u bolnykh mnozhestvennojj mielomojj // Sibirskijj medicinskijj zhurnal. 2006. № 7. S. 28 – 30.
Zubrikhina G.N., Blindar V.N., Matveeva I.I. i dr.Ocenka laboratornykh pokazatelejj, kharakterizujushhikh fukcionalnoe sostojanie gemopoehza u onkogematologicheskikh bolnykh na fone vysokodoznojj khimioterapii i autotransplantacii gemopoehticheskikh stvolovykh kletok // Vestnik RONC im. N.N.Blokhina RAMN. 2011. T. 22. № 4. S. 46 – 54.
Patent № 2132071 (RF). Sposob differencialnojj diagnostiki zlokachestvennykh novoobrazovanijj shhitovidnojj zhelezy i uzlovogo netoksicheskogo zoba // T.N. Panova, M.A. Epinetov.
Hann H.W.L., Levy H.M., Evans A.E.Serum ferritin as a guide to therapy in neuroblastoma // Cancer Res. 1980. V. 40. P. 411–1413.
Hann H.W.L., Evans A.E., Siegel S.E. et al. Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: The Children\'s Cancer Study Group experience // Cancer Res. 1985. V. 45. P. 2843–2848.
Milman N., Pedersen L. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer // Oncology reports. 2002. V. 9. P. 193 – 198.
Wahlin A., Lorenz F., Fredriksson M. et al. Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell graft // Med. Oncol. 2010 Apr 15. [Epub ahead of print] PMID 20393815 [PubMed – as supplied publisher].
Altes A., Remacha A.F., Sarda P. et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study // Ann. Haematol. 2007. V. 86. P. 443 – 447.
Miceli M.H., Dong L., Grazziutti M.L. et al. Iron overloadis a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients // Bone Marrow Transpl. 2006. V. 37. P. 857 – 864.
Pullarkat V., Blanchard S., Tegtmeier B. et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation // Bone Marrow Transpl. 2008. V. 42. P. 799 –805.
Herget-Rosenthal S., Gerken G., Philipp T. et al. Serum ferritin and survival of renal transplant recipients: a prospective 10-year cohort study // Transpl. Int. 2003. V. 16. P. 642 – 647.
Kim Y.R., Kim J.S., Cheong J.W. et al. Transfusion-associated iron overload as an averse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies // Acta Haematol.2008. V. 120. P. 182 – 189.
Blindar V.N., Zubrikhina G.N. Matveeva I.I., Dobrovolskaja M.M. Ferritin, rastvorimye receptory transferrina, ehritropoehtin u onkologicheskikh bolnykh s anemicheskim sindromom // KHI Rossijjskijj onkologicheskijj kongress. M. 2007.S. 196.
Pavlov A.D., Morshhakova E.F., Rumjancev A.G. Anemija pri zlokachestvennykh novoobrazovanijakh: patogenez i lechenie rekombinantnym ehritropoehtinom // Sovremennaja onkologija. 2002. T. 4. №2 S. 50 – 54.
Weiss G.Pathogenesis and treatment of anaemia of chronic disease // Blood Rev. 2002. V. 16. №3. P. 87 – 96.
Zubrikhina G.N., Blindar V.N., Matveeva I.I.Anemicheskijj sindrom u onkologicheskikh bolnykh // Vestnik RONCim. N.N. Blokhina RAMN. 2009. T. 20. № 4. S. 57 – 62.
Zhu Y. The correlation of cytokines TNF alpha, IFN-gamma, Epo with anemia in rheumatoid arthritis / Y. Zhu, D. Ye, Z. Huang // Zhonghua Xue Ye Xue Za Zhi. 2000. № 21. R. 587–590.
Nemeth E., Rivera S., Gabajan V.J. IL6 mediates hypoferremia inducing the synthesis of the iron regulatory hormone hepcidin // V. J. Clin. Inv. 2004. № 113. R. 1271 – 1276.
Knutson M.D., Oukka M., Koss L.M., Aydemir F., Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin / Knutson M.D. // Proc. Natl. Acad. Sci. USA. 2005. № 102. R. 1324 – 1328.
Hguyen N.B., Callaghan K.D., Ghio A.J. et al. Hepcidin expression and iron transport in alveolar macrophages // Am. J. Physiol. Lung Cell Mol. Physiol. 2006. V. 291. №3. P. 417– 425.
Chaston T., Chung V., Mascarenhas M., Marks J. Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells // Gut. 2008. № 57. R. 374 – 382.
Cadet E., Gadenne M., Capront D., Rochette J. Donnes recentes sur metabolisme du fer: un etat de transition // La revue de medecine intern. 2005. № 26. P. 315 – 324.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.